TECVAYLI™ (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Read the Full Prescribing Information here, including Boxed Warning.

Sign Up to Stay Updated About TECVAYLI

Janssen Biotech, Inc., our affiliates, and our service providers will use the information you provide to send you TECVAYLI information updates. Our Privacy Policy further governs the use of the information you provide.


First Name is required.
Last Name is required.
Valid Email is required.
Valid ZIP Code is required.
Specialty is required.